



"Each day, our team comes to work excited by the challenge and opportunity to work at the forefront of a new field of medicine. We are driven by the promise of synthetic biology and by the new possibilities for better health that we believe we can bring to patients."


— Dr. Aoife Brennan
President and CEO

Synlogic is a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology.

A New Strategy to Treat Disease

Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic Biotics, to improve patients' lives.

Synthetic Biotics are living probiotics that have been genetically engineered to perform specific functions in the GI tract targeting validated biology. They have the potential to treat a range of conditions including rare diseases, metabolic conditions, immunologic and inflammatory diseases. Because Synthetic Biotics are orally administered and are based on familiar probiotics as their delivery method, or chassis, they offer a potentially convenient and safe approach to treatment.




Synthetic Biotics have the potential to treat a broad range of diseases.

Progress in Drug Development

Synlogic's pipeline includes a lead program in phenylketonuria (PKU) which has demonstrated proof of concept with plans underway to start a pivotal, Phase 3 study. The company is also advancing additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. Synlogic also has research collaborations established with Roche and Ginkgo Bioworks.

Our Pipeline



"People think this isn't too bad, I look okay. But this is a lifelong burden."

— Les, living with PKU

"HCU is all I think about every day. I am reminded by my symptoms, by my need to stick with my diet. I cannot endure more seizures or a third stroke."

— Joanna, living with HCU

Targeting Significant Areas of Unmet Need

Rare Metabolic Diseases

Phenylketonuria (PKU) is a rare metabolic disease that is diagnosed at birth and caused by an inherited inability to break down the amino acid phenylalanine (Phe). A large majority of patients remain untreated due to limitations in currently available treatment options.

Homocystinuria (HCU) is a rare metabolic disease in which patients cannot metabolize the amino acid homocysteine, leading to its excessive accumulation with risks including thromboembolism, skeletal abnormalities, and intellectual disability. Treatment options are currently limited due to efficacy and tolerability.

Enteric Hyperoxaluria

Enteric hyperoxaluria is a disease characterized by high levels of urinary oxalate leading to chronic, recurrent kidney stones and renal damage, including chronic kidney disease (CKD) and end-stage renal disease (ESRD). There are no FDA-approved treatment options available today that can reduce oxalate levels and the associated risks.

Immunologic & Inflammatory Disease

Synlogic is also advancing research to assess the ability of novel Synthetic Biotics to treat inflammatory bowel disease.

Our Commitment

Synlogic is deeply committed to patients who are burdened by living with unmet medical needs, every day. The company understands the need for new treatment options and is tirelessly working on behalf of the rare disease community.

Synlogic

301 Binney Street
 #402
 Cambridge, MA 02142